An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
NCT ID: NCT01686581
Last Updated: 2018-11-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
641 participants
OBSERVATIONAL
2012-07-23
2016-10-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BOTOX® Prophylaxis in Patients With Chronic Migraine
NCT01432379
Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
NCT02502123
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
NCT01516892
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
NCT01662492
Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
NCT03193359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BOTOX®
BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
botulinum toxin Type A
Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
botulinum toxin Type A
Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Current participation in Allergan's Botox Chronic Migraine Post-Authorisation Safety Study (protocol 191622-110).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nicole Strickling
Aachen, , Germany
Manfred Oberling
Bad Camberg, , Germany
Kathrin Krome
Bamberg, , Germany
Heike Förster
Baunatal, , Germany
MVZ Schmerzzentrum Berlin
Berlin, , Germany
Christoph Engelmann
Berlin, , Germany
Andreas Kupsch
Berlin, , Germany
Hans-Dieter Zug
Böblingen, , Germany
Andreas Schwittay
Böhlen, , Germany
Bezirksklinikum Mainkofen
Deggendorf, , Germany
Ulrike Kirchhöfer
Erfurt, , Germany
Michael Kiszka
Erfurt, , Germany
Astrid Gendolla
Essen, , Germany
Jürgen Hamacher
Essen, , Germany
Schmerzzentrum Rhein Main in Frankfurt
Frankfurt, , Germany
Bernhard Hellwig
Freiburg im Breisgau, , Germany
G. Müller-Schwefe
Göppingen, , Germany
Borries Kukowski
Göttingen, , Germany
Peter Asmus
Guelders, , Germany
Veit Becker
Hamburg, , Germany
Hanno Jaeger
Hamburg, , Germany
Klaus Gerlach
Hanover, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Ulrike Köhler
Heidelberg, , Germany
Frank Halbgewachs
Heidenheim, , Germany
Dirk Buschmann
Herford, , Germany
Rotes Kreuz Krankenhaus Kassel
Kassel, , Germany
Schmerzklinik Kiel
Kiel, , Germany
Migräne-Klinik Königstein
Königstein, , Germany
Neuroscience Center Leipzig
Leipzig, , Germany
Dietmar Walter Noack
Limburgerhof, , Germany
Lothar Klimpel
Limburgerhof, , Germany
St.-Marien-Hospital GmbH
Lünen, , Germany
Olaf Günther
Magdeburg, , Germany
Institut für Forschung und Prävention
Mainz, , Germany
Stephan Nautscher-Timmermann
Mühlhausen, , Germany
Praxis für Neurologie und SchmerzMedizin
München, , Germany
Matthias Haslbeck
München, , Germany
Klinikum der Universität München - Großhadern, Neurologische Klinik
München, , Germany
Neurologie und Kopfschmerzzentrum Münchner Freiheit
München, , Germany
Schmerztherapiezentrum Münster
Münster, , Germany
Roland Leger
Nuremberg, , Germany
Dr. Becker Rhein-Sieg-Klinik
Nümbrecht, , Germany
Matthias Röder
Oberhausen, , Germany
mediPlan Klinik GmbH
Ostfildern, , Germany
Frank Freitag
Potsdam, , Germany
Universität Rostock, Klinik für Neurologie
Rostock, , Germany
Ingo Palutke
Stadtroda, , Germany
Heinz Peter Herbst
Stuttgart, , Germany
Anselm Kornhuber
Ulm, , Germany
Universitätsklinikum Ulm, Klinik für Neurologie
Ulm, , Germany
Volker Heinicke
Weimar, , Germany
Parkinson-Klinik Wolfach
Wolfach, , Germany
Michaela Krause
Wolfratshausen, , Germany
Jochen Ulzheimer
Würzburg, , Germany
Dorothea Händel
Zwickau, , Germany
Ospedale Careggi
Florence, , Italy
Istituto Neurologico Carlo Besta di Milano
Milan, , Italy
Azienda Ospedaliera Sant'Andrea
Roma, , Italy
Hodeverket Headache Clinic
Sandnes, , Norway
LLC Neyroklinika
Khabarovsk, , Russia
LLC Center for Interdisciplinary Dentistry and Neurology
Moscow, , Russia
LLC Clinic Sesil +
Moscow, , Russia
LLC University Headache Clinic
Moscow, , Russia
LLC Sibneuromed
Novosibirsk, , Russia
Hospital Universitario de Burgos
Burgos, , Spain
Hospital Universitario Reina Sofía
Córdoba, , Spain
Hospital Universitario Virgen de la Victoria
Málaga, , Spain
Hospital Central de Asturias
Oviedo, , Spain
Hospital Santiago de Compostela
Santiago de Compostela, , Spain
Hospital Galdácano
Usansolo, , Spain
Löfvingkliniken
Gothenburg, , Sweden
Centralsjukhuset i Karlstad
Karlstad, , Sweden
Läkarhuset Utsikten
Stockholm, , Sweden
Spire Hull and East Riding Hospital
Anlaby, , United Kingdom
University Hospital of North Staffordshire, Neurology Research Unit
Stoke-on-Trent, , United Kingdom
Mid Yorkshire NHS Trust
Wakefield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ahmed F, Gaul C, Kollewe K, Singh RC, Sommer K. Real-World Safety and Efficacy of 156 U - 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study. BMC Neurol. 2025 May 6;25(1):197. doi: 10.1186/s12883-025-04087-7.
Kollewe K, Gaul C, Gendolla A, Sommer K. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. J Headache Pain. 2021 Jun 2;22(1):50. doi: 10.1186/s10194-021-01260-4.
Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P; REPOSE Principal Investigators. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019 Mar 7;20(1):26. doi: 10.1186/s10194-019-0976-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAF/AGN/NS/CM/002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.